TY - JOUR
KW - Health Services Accessibility
KW - Humans
KW - Naltrexone/therapeutic use
KW - Narcotic Antagonists/therapeutic use
KW - Opioid-Related Disorders/drug therapy/nursing
KW - Outpatients
KW - Patient Education as Topic
KW - Primary Health Care
KW - United States
AU - T. M. Padgett
A1 - 
AB - Substance use disorder (SUD), more specifically opioid use disorder, is a national epidemic. Although there is an emphasis on treatment and increasing treatment locations, there continues to be a gap between the number of people with SUD and the number of treatment centers. To help narrow this gap, some primary care clinicians started providing medication-assisted treatment (MAT) on an outpatient basis in their offices. This option enables clinicians to provide treatment in their own communities, which increases access to treatment and decreases costs. It also enables the clinician and the person with SUD/opioid use disorder to build a relationship, which many clinicians believe is the foundation of successful treatment. The clinician, whether a doctor, a physician assistant, or an advanced practice nurse, has to obtain a Drug Addiction Treatment Act 2000 waiver to provide MAT beyond naltrexone, which has a required educational program and includes a limitation on the number of clients. Conversely, a possible drawback to this type of treatment is the potential for the disruption of continuity of care with regard to psychotherapy treatment. Federal law mandates that therapy is available and provided to people receiving MAT. The clinician may not be able to provide this service and would need to refer the person with SUD for psychotherapy treatment. It may be clinically significant for a type of follow-up communication to be implemented so that the clinician and the therapy provider can maximize SUD treatment success.
AD - Tonja M. Padgett, RN, DNP, ACNS-BC, Indiana University School of Nursing, Indianapolis.
BT - Journal of addictions nursing
C5 - Education & Workforce; Healthcare Policy; Opioids & Substance Use
CP - 4
CY - United States
DO - 10.1097/JAN.0000000000000305
IS - 4
JF - Journal of addictions nursing
LA - eng
M1 - Journal Article
N2 - Substance use disorder (SUD), more specifically opioid use disorder, is a national epidemic. Although there is an emphasis on treatment and increasing treatment locations, there continues to be a gap between the number of people with SUD and the number of treatment centers. To help narrow this gap, some primary care clinicians started providing medication-assisted treatment (MAT) on an outpatient basis in their offices. This option enables clinicians to provide treatment in their own communities, which increases access to treatment and decreases costs. It also enables the clinician and the person with SUD/opioid use disorder to build a relationship, which many clinicians believe is the foundation of successful treatment. The clinician, whether a doctor, a physician assistant, or an advanced practice nurse, has to obtain a Drug Addiction Treatment Act 2000 waiver to provide MAT beyond naltrexone, which has a required educational program and includes a limitation on the number of clients. Conversely, a possible drawback to this type of treatment is the potential for the disruption of continuity of care with regard to psychotherapy treatment. Federal law mandates that therapy is available and provided to people receiving MAT. The clinician may not be able to provide this service and would need to refer the person with SUD for psychotherapy treatment. It may be clinically significant for a type of follow-up communication to be implemented so that the clinician and the therapy provider can maximize SUD treatment success.
PP - United States
PY - 2019
SN - 1548-7148; 1088-4602
SP - 238
EP - 241
EP - 
T1 - The Advantages and Disadvantages of Medication-Assisted Treatment in Primary Care Offices
T2 - Journal of addictions nursing
TI - The Advantages and Disadvantages of Medication-Assisted Treatment in Primary Care Offices
U1 - Education & Workforce; Healthcare Policy; Opioids & Substance Use
U2 - 31800513
U3 - 10.1097/JAN.0000000000000305
VL - 30
VO - 1548-7148; 1088-4602
Y1 - 2019
Y2 - Oct/Dec
ER -